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Abstract
Genome-wide association (GWA) studies are a powerful approach for identifying novel genetic
risk factors associated with human disease. A GWA study typically requires the inclusion of
thousands of samples to have sufficient statistical power to detect single nucleotide
polymorphisms (SNPs) that are associated with only modest increases in risk of disease given the
heavy burden of a multiple test correction that is necessary to maintain valid statistical tests. Low
statistical power and the high financial cost of performing a GWA study remains prohibitive for
many scientific investigators anxious to perform such a study using their own samples. A number
of remedies have been suggested to increase statistical power and decrease cost, including the
utilization of free publicly available genotype data and multi-stage genotyping designs. Herein, we
compare the statistical power and relative costs of alternative association study designs that use
cases and screened controls to study designs that are based only on, or additionally include, free
public control genotype data. We describe a novel replication-based two-stage study design, which
uses free public control genotype data in the first stage and follow-up genotype data on case-
matched controls in the second stage, that preserves many of the advantages inherent when using
only an epidemiologically matched set of controls. Specifically, we show that our proposed two-
stage design can substantially increase statistical power and decrease cost of performing a GWA
study while controlling the type I error rate that can be inflated when using public controls due to
differences in ancestry and batch genotype effects.
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Introduction
Large-scale commercial genotyping platforms have facilitated the identification of numerous
common single nucleotide polymorphisms (SNPs) that are associated with complex genetic
diseases. The high cost of genome-wide association (GWA) studies has lead to the
utilization of multi-stage study designs. Two-stage genotyping designs typically involve
genotyping a fraction of the entire sample on a commercial genotyping platform containing
all SNPs of interest in stage 1, performing systematic tests of association using stage 1
samples, and genotyping stage 2 samples on only the SNPs of greatest interest as determined
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in stage 1 (Satagopan et al., 2002). Two-stage genotyping designs have been shown to
maintain power comparable to a single-stage study employing all samples while
substantially decreasing overall genotyping costs (Kraft, 2006;Satagopan et al.,
2002;Satagopan et al., 2004;Skol et al., 2006;Skol et al., 2007;Thomas et al., 2004;Wang et
al., 2006). The data collected from the second stage of a two-stage GWA study is either
analyzed separately as a replication-based sample or the data is combined with data from the
first stage and the combined data is analyzed jointly. A recent alternative approach for
reducing the cost of a large-scale case-control genetic association study and to increase the
statistical power to detect an association when present is to use freely available genotype
data on a large number of subjects from previous genome-wide association scans as control
data in the current study. The effective use of a large public control dataset for comparison
with multiple case datasets for different phenotypes was illustrated by the Wellcome Trust’s
Case Control Collaboration (WTCCC) GWA study on 14,000 cases of seven common
diseases and 3,000 shared controls (Wellcome Trust Case Control Consortium, 2007). In this
study, based on British subjects of European descent, the WTCCC identified 24 independent
associations (p < 5 × 10−7) for bipolar disorder, coronary artery disease, Crohn’s disease,
rheumatoid arthritis, type 1 diabetes and type 2 diabetes using 2,000 independent cases for
each disorder.
For investigators that have collected a well-matched group of cases and controls who wish
to preserve many of the benefits of their sample collection design, we describe a replication-
based two-stage case-control genetic association study design that uses free genotype data
from public controls in stage 1, well-matched study controls in stage 2, and study cases
distributed over stages 1 and 2. We compare the power and relative cost of our two-stage
approach to single-stage approaches that strictly use either free public control genotype data
or genotype data from study controls and to the single-stage approach that combines public
and study controls. We discuss the advantages and limitations of each of the four sampling
designs while considering the impact of ancestrally poorly-matched public controls and
batch genotype effects. We show that the proposed replication-based two-stage design
controls the overall type I error rate and has increased power over studies that exclude public
controls.
Material and Methods
We assumed an investigator had a sample of NA study cases, NU study controls and access to
free genotype data on NPU public controls. We further assumed that study controls were
screened for disease and that public controls were not screened for disease. We performed a
series of calculations over a range of alternative models comparing the power achieved in an
association study using four different sampling approaches: 1) a single-staged association
study that used all NA study cases and NU study controls; 2) a single-staged association study
that utilized all NA study cases and NPU public controls; 3) a single-staged association study
that used all NA cases and combined all NU study and NPU public controls; 4) a two-staged
replication-based study that used all NPU public controls in stage 1, all NU study controls in
stage 2 and all NA cases apportioned between stages 1 and 2. We assumed an underlying
multiplicative genetic mode-of-inheritance risk model for a bi-allelic locus with alleles D
and d and corresponding allele frequencies of fD and fd, respectively. For each alternative
model, we set the population frequency of the susceptibility allele D in the general
population, the prevalence (K) of the disease in the population, and the locus specific genetic
relative risk (GRR) = Pen(DD)/Pen(Dd) = Pen(Dd)/Pen(dd), where Pen(dd), Pen(Dd), and
Pen(DD) were the penetrances for the dd, Dd, and DD genotypes, respectively. Consistent
with many genetic power calculators, our power calculations are for the main effects of a
directly genotyped locus and, as such, do not rely on additional assumptions regarding the
extent of linkage disequilibrium between this locus and an untyped causal locus. All power
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analyses were programmed into the freely available statistical software R version 2.4.1 (R
Development Core Team, 2006).
Single-stage Power Calculations
Assuming Hardy-Weinberg equilibrium in the general population from which the cases and
controls were selected, we used our model assumptions (allele frequencies, disease
prevalence and GRR) to calculate the penetrance functions and we used Bayes’ theorem to
ascertain the conditional probability of each genotype given affection status, Pji, where j
indexes affection status and i = 0 (dd), 1 (Dd), 2 (DD) indexes genotype. Namely, for the
cases these probabilities were PA0 = Pr(dd | case), PA1 = Pr(Dd | case), and PA2 = Pr(DD |
case) and for the unaffected (screened) controls the probabilities were PU0 = Pr(dd |
unaffected control), PU1 = Pr(Dd | unaffected control), PU2 = Pr(DD | unaffected control).
We assumed no disease misclassification among study cases or screened study controls.
Derivations of the conditional genotype probabilities are provided for the multiplicative
model in the Supplementary materials. For public controls, the genotype probabilities were
set to the genotype probabilities in the general population, namely PPU0 = fd2, PPU1 = 2fd fD,
PPU2 = fD2, since affection status was not assumed to be known.
We calculated asymptotic power for the Cochran-Armitage trend test (Armitage,
1955;Cochran, 1954) by specifying the non-centrality parameter based on work by Chapman
and Nam (Chapman and Nam, 1968) and we set the vector of scores to x = (0, 1, 2) for
genotypes (dd, Dd, DD), respectively (Slager and Schaid, 2001). In particular, the non-
centrality parameter, explicitly stated by Ahn et al. (Ahn et al., 2007), was
where NA and NU (or optionally NPU) were the sample sizes of the cases and screened (or
public) controls, respectively, xi was the score for the i-th genotype (i = 0, 1, 2 for genotypes
dd, Dd, DD), and PAi and PUi were the probabilities of the i-th genotype for the cases and
controls, respectively. Power was then taken to be 1 − β, where β was the type II error of the
non-central χ2 distribution with 1 degree of freedom and non-centrality parameter λ,
evaluated at the 100(1 −αBonferroni) percentile of the central χ2 distribution with 1 degree of
freedom. For single-stage designs, the overall family-wise error rate was set to α = 0.05 by
using a Bonferroni corrected significance threshold αBonferroni = 0.05/M, where M was the
number of markers evaluated.
Replication-Based Two-stage Power Calculations
Using the formulas described above for one-stage power, we calculated power for a
replication-based two-stage design. For a replication-based two-stage design, the overall
power for a SNP was simply calculated as the product of the power for the first stage times
the power of the second stage. Following the notation in Skol et al. (Skol et al., 2006), the
power for the first-stage was calculated using a significance threshold defined as the
proportion of markers followed in stage 2, πmarkers. Power for the second-stage was
calculated using a significance threshold equal to 2α/(M π markers), i.e. the Bonferroni
corrected cutoff for a one-sided test that requires the direction of the SNP main effect to be
the same in stage 1 and 2 samples.
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We restricted the number of SNPs for follow-up analysis in stage 2 to be values that
approximate numbers that would typically be considered given today’s currently available
commercial genotyping platforms. Namely, we considered follow-up platforms of size 100,
1,500, 7,500, and 16,500 SNPs. For each follow-up genotyping platform, we found the
optimal proportion of cases, πcases, to be genotyped in stage 1 that optimized the power of
the two-stage design. Specifically, we used the “optimize” function in R to search for the
maximum power in the continuous space of πcases. This method combines the golden section
search and successive parabolic interpolation algorithms.
Examples of Power Approximations for 1- and 2-Stage Designs
We calculated power for a GWA scan on M = 500,000 SNPs based on a study sample of NA
= 2,000 study cases and NU = 2,000 study controls to demonstrate the difference in power
between the competing approaches. We assumed a multiplicative model with a GRR = 1.3,
and a susceptibility allele frequency fD = 0.3 in the general population. We considered a
wide range of disease prevalence values of K = 1×10−4, 0.01, 0.05, 0.1, 0.25, and 0.5 and we
assumed available genotype data on samples of NPU = 2,000, 5,000 and 10,000 public
controls. We calculated power for the single-stage designs (using only study controls, only
public controls, or both control samples combined) and for the optimal replication-based
two-stage design. For each optimal two-stage model we provided the power estimate from
the follow-up platform that provided the greatest power. Finally, in order to test how power
of the 2-stage designs for the four proposed follow-up platforms were impacted by different
combinations of susceptibility allele frequency and GRR, we calculated power with K =0.10
(assuming NPU = 5,000) using susceptibility allele frequencies of fD = 0.1, 0.3 and 0.5 and
GRRs ranging from 1.2 to 1.5. Additional power calculations for other study designs using
the Cochran-Armitage trend test, the general two-degree of-freedom test of association, and
both dominant and recessive models are provided in the Supplementary material.
Impact on Power of Ancestrally Poorly-Matched Public Controls and Batch Genotype
Effects
Ancestrally poorly-matched public controls and batch genotype effects that can occur when
genotyping study samples and public controls from different populations at different times
can have detrimental effects on power and type I error. We evaluated the impact of these
factors for a study design that included 2,000 study cases, 2,000 study controls, and 5,000
public controls for a multiplicative disease model with susceptibility allele frequency fD =
0.3, K = 0.10 and GRR = 1.3 (Model 1).
We assessed the impact of ancestrally poorly-matched public controls on power by
simulating two genetically-admixed populations (our study population and the public control
population). We assumed our study population consisted of individuals derived from two
ancestral populations (POP1 and POP2), with subjects having a mean proportion of POP1
equal to 0.25 and standard deviation equal to 0.15. Furthermore, we assumed that study
cases had a mean proportion of POP1 ancestry equal to 0.221 and study controls had a mean
proportion of POP1 ancestry equal to 0.253. These values are consistent with the estimated
proportion of European ancestry in African American prostate cancer cases and controls
(Haiman et al., 2007). For public controls, we allowed the mean proportion of POP1
ancestry to vary between 0.10 and 0.40 and assumed a fixed standard deviation of 0.15. We
maintained the overall frequency of the susceptibility allele to be fD = 0.30 in the study
population, but varied fD between 0.00 and 0.60 in POP1 (in both the study and public
control populations). Finally, we assumed that any extreme outliers, such as individuals with
misreported ethnicity, would be identified and removed prior to testing for association.
Simulated data sets (n = 10,000) were analyzed using logistic regression models, with
covariate adjustment for the proportion of POP1 descent of each subject to control for
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population stratification as would be routinely done in a GWA study using analytic methods
such as principal components, for the one- and two-stage designs under the null model
(GRR = 1.0) and the alternative model described above.
Modern commercial genotyping platforms have increasingly high accuracy in genotype
calling, but small systematic biases in genotyping calling when genotyping cases and
controls at different times or on different platforms can create artificial differences in
genotype frequencies between them. Careful study design can alleviate these concerns when
genotyping study cases and controls at the same time, but using public controls will always
be a concern. We assessed the impact of batch genotype effects on power for the one- and
two-stage designs. We assumed that batch genotype effects would result in systematic and
over or under calling of the susceptibility allele on an allele-by-allele basis (i.e. the
probability an allele in a genotype being miscalled was assumed to be independent of the
calling for the other allele). We additionally assumed that all subjects genotyped at the same
time were subject to the same batch effect, effecting any cases and controls genotyped
together equally. Over or under calling of the susceptibility allele was allowed to occur with
different probabilities for each genotyping platform (e.g. for our proposed two-stage design
there were three different genotyping platforms where the susceptibility allele could either
be over or under called – the platform used for public controls, the genome-wide panel for a
subset of the cases, and the follow-up platform for the remaining cases and all study
controls). Genotype batch effects were modeled by modifying the genotype probabilities in
our power calculator. For example, under Model 1 the probabilities of the three genotypes
for public controls (fD = 0.30) when there were no genotype batch effects were set to 0.09,
0.42 and 0.49 for the DD, Dd and dd genotypes, respectively. If the batch effects resulted in
the susceptibility allele D systematically being over-called with error probability + 0.01 (i.e.
the non-susceptibility allele d is erroneously reported as the susceptibility allele D with
probability 0.01), then the probabilities for the three genotypes DD, Dd and dd were set to
0.094249 [0.09 + 0.01(0.42) + (0.01)2(0.49)], 0.425502 [(0.99)(0.42) + 2(0.99)(0.01)(0.49)]
and 0.480249 [(0.99)2(0.49)], respectively. This calculation takes into consideration that
subjects with true genotype dd could be mistakenly scored Dd (with probability =
2×0.99×0.01) or DD (with probability (0.01)2) and subjects with true genotype Dd could be
mistakenly scored DD (with probability 0.01). We did not assume any additional random
error in our calculations (in the above example, subjects with true genotype DD were
assumed to be scored DD with probability = 1). We considered systematic allele calling
error probabilities for a given genotype platform of + 0.01, 0.00, and − 0.01, where + (−)
corresponds to erroneously over (under) calling of the susceptibility allele.
The impact of batch genotype effects on power were evaluated under the null hypothesis of
no association and under the alternative model described above for the one and two-stage
designs. These calculations were performed under the assumption that either the specific
SNP under consideration was the only SNP subject to batch effects or that there existed a
systematic bias due to batch effects that impacted all SNPs. Under the former scenario, we
used the same significance thresholds described previously for the one- and two-stage
studies. For the latter scenario, we assumed a baseline 10% mean systematic inflation of the
chi-square test statistics across the genome (mean value test statistic, μ=1.10) for all SNPs
evaluated in the one-stage study design based only on public controls. We assumed no
inflation (μ=1.00) for the test statistics of the one-stage study design based only on study
controls and for the test statistics from stage 2 analyses of the replication-based two-stage
study designs (because cases and controls would be genotyped at the same time in stage 2).
The mean systematic inflation of the test statistics, μ − 1, is equal to λ ~ Np(1−p)Δ2 (i.e., the
non-centrality parameter of a chi-square test with 1 df), where N is the total sample size, p is
the proportion of cases in the sample and Δ is the metric reflecting the difference in
genotype frequencies between cases and controls due to batch effects. Consequently, the
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magnitude of the systematic inflation of the test statistics does not impact all study designs
equally. Hence, we recalculated the mean inflation of the test statistics for the one-stage
design with both study and public controls and for stage 1 of each replication-based two-
stage study design (based on the number of cases included in stage 1). For the one-stage
studies that include public controls, we calculated power after correcting for the systematic
batch effects across all SNPs by multiplying the critical value of the 1 df chi-square
distribution corresponding to p = 1.0×10−7 (i.e. 28.373) by the mean test statistic value, μ
(Reich and Goldstein, 2001). For each two-stage study, the stage 1 test-statistic critical value
was multiplied by the corresponding mean test statistic value, μ, determined by the stage 1
sample composition.
Example of Genotyping Costs for Different Genotype Sampling Strategies
To understand the financial impact of the different genotyping sampling strategies, we
estimated the relative total experimental cost of each genotype sampling design for a GWA
study based on M = 500,000 SNPs using NA = 2,000 study cases, NU = 2,000 screened study
controls and NPU = 5,000 public controls. We assumed a multiplicative trait with a
prevalence K = 0.1, GRR = 1.3 and fD = 0.3 (Model 1). We calculated the relative total costs
of performing the three single-stage studies that used either study or public controls or both.
For these single-stage sampling designs, all study samples were assumed to be genotyped on
all 500,000 SNPs; genotype data for public controls were assumed to be available at no
expense. In addition, we calculated the relative total cost of the optimal (highest power)
replication-based two-stage study design for each follow-up platform. For the purpose of our
calculations, we assumed the Illumina Human660W-Quad platform would be used for
genotyping 500,000 viable SNPs in stage 1 and Illumina’s GoldenGate 96, 384 and 1,536
SNP panels and Illumina’s Custom iSelect Infinium 7,600 and 16,720 SNP panels would be
used as the follow-up platforms for stage 2. Given that genotyping costs are constantly
changing, rather than using dollar amounts, we report the relative total cost of genotyping all
study subjects based on current prices. Using the cost of genotyping 500,000 SNPs for an
individual sample on a genome-wide panel as a baseline, the relative total cost of genotyping
16,000, 7,500, 1,500, and 100 SNPs for that sample were assumed to be 1/2, 1/3, 1/5, 1/10
and 1/12 of the cost, respectively, based on the most recent genotype prices at the CIDR
genotyping facility (www.cidr.jhmi.edu/pricing.pdf).
Skol et al. (Skol et al., 2006) demonstrated that a joint-analysis two-stage study design could
effectively achieve equivalent power to a single-stage study for a fraction of the cost.
Consequently, for the three single-stage sampling designs, we also estimated the relative
cost of performing a joint-analysis two-stage association study for each follow-up platform.
For each combination of sampling design and follow-up platform, we performed a series of
simulations to identify the least expensive joint-analysis two-stage sampling design that
obtained an estimated power within 0.01 of the power obtained from the corresponding
single-stage study. For the sampling design that used only public controls, cases were
divided between stages 1 and 2 while all public controls were assumed to be available in
stage 1. For the sampling design that included both study and public controls, all study
controls were assumed to be genotyped in stage 2, and all public controls were assumed to
be available in stage 1. Cases were divided between stages 1 and 2.
Results
We performed power calculations for a range of study designs and disease models. Power is
described for the frequency of the risk allele in the general population (the frequency of the
risk allele in cases and study controls for different values of K are provided in the table
footnotes). Not surprisingly, our results showed that including free genotype data from
public controls increases statistical power over studies that do not include these data (Table
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1). The single-stage study with both public and study controls noticeably outperformed the
replication-based two-stage study using the same samples. Power for the proposed
replication-based two-stage design was typically greater than the power of the one-stage
design based only on study controls. Overall, the same general patterns of results were
observed when varying GRR and frequency of the disease susceptibility allele
(Supplementary Figure 1), when analyzing the genotype data using a general (co-dominant)
2-df inheritance model (Supplementary Table 2), and when considering dominant or
recessive genetic inheritance models (Supplementary Tables 3 and 4, respectively).
For the replication-based two-stage design, we observed that the optimal choice of the
proportion of cases, πcases, to be genotyped in stage 1 varied considerably between the
different choices of stage 2 genotyping platforms (as expected, a larger proportion of cases
were necessary to be genotyped in stage 1 for the smaller follow-up platforms) but,
importantly, varied little within a given platform across the considered range of GRRs and
disease allele frequencies (Table 2). We note that for a given follow-up platform, the
optimal choice of πcases was also insensitive to analytic strategy (i.e. similar optimal values
of πcases were observed for the general 2-df test as for the trend test) (Supplementary Table
5) and genetic inheritance model (i.e., similar optimal values of πcases were also observed for
the dominant and recessive models) (Supplementary Tables 6 and 7). These results suggest
that it is reasonable to use the proportion of cases, πcases, to be genotyped in stage 1 that
optimizes power for a replication-based two-stage study design based on a single specific
alternative model and expect that power should be near optimized by this choice of πcases
across a range of alternative genetic models when using the same follow-up platform.
Ancestrally Poorly-Matched Public Controls and Batch Genotype Effects
All study designs maintained power near levels obtained under negligible population
stratification when the proportion of POP1 ancestry in public controls was within 0.05 of the
proportion of POP1 ancestry in the study population regardless of the frequencies of the
disease-susceptibility allele in the POP1 and POP2 ancestral populations (Table 3). Power
for the one-stage design that only included public controls dropped noticeably when the
proportion of POP1 ancestry in public controls was either 0.10 or 0.40. Under these two
scenarios, the greatest decline in power was observed when the susceptibility allele was
more (for proportion POP1 = 0.10) or less (for proportion POP1 = 0.40) frequent in the
POP1 ancestral population. Power for the two-stage design with follow-up on 100 of the
best SNPs dropped when the proportion of POP1 ancestry in public controls was equal to
0.40. Power for the one-stage design with both public and study controls and the remaining
two-stage designs stayed relatively stable across the range of considered proportions of
POP1 ancestry in public controls.
Systematic genotyping errors (over or under calling of the susceptibility allele) decreased
power modestly for the one-stage design with only study controls (Table 4). For the one-
stage designs that included public controls, genotyping errors in opposite directions on the
two genotyping platforms (e.g. over calling susceptibility allele in public controls and under
calling susceptibility allele in study samples) had a major impact on power. For the single-
stage study with only public controls, in the absence of batch effects (for both the individual
SNP and for all other SNPs across the genome) the power was 0.90. Over calling the
susceptibility allele in the public controls and under calling the susceptibility allele in cases
(each with probability of 0.01 per allele) resulted in power decreasing to 0.53. Conversely, if
the susceptibility allele was under called in the public controls and over called in the cases
then power increased to 0.99. A similar pattern, but less dramatic differences, were observed
for the single-stage study design with both public and study controls. Both single-stage
studies that include public controls experienced some loss in power when accounting for the
mean systematic inflation in the test statistics for all other SNPs across the genome due to
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batch genotype effects. Regardless of batch effects, the single-stage study that includes both
public and study controls always had greater power than the single-stage study with only
study controls.
Batch effects also impacted the power of the two-stage studies (Table 5). The two-stage
studies that were based on the larger follow-up platforms were less impacted by batch
effects than the studies that were based on the smaller follow-up platforms (the range in
power for the 16500 platform was 0.74–0.87 while the range for the 100 platform was 0.70–
0.95, before factoring in the impact of the mean systematic inflation of test statistics across
the genome). Accounting for systematic batch effects on other SNPs across the genome
(which increased the significance threshold in stage 1 required for inclusion of the SNP into
stage 2) had near negligible impact on power for the larger follow-up platforms but resulted
in small declines in power for the smaller follow-up platforms. Even after factoring in the
impact of batch genotype effects, the two-stage study designs typically outperformed the
one-stage study design based only on study controls.
Cost Savings Including Public Controls
In addition to increased power, in Table 6 we illustrate that substantial cost savings can be
achieved for a GWA study when including public controls. We compared the relative cost of
one- and two-stage study designs that include study controls, public controls or both. We
required the power of the joint-analysis two-stage study designs to be within 0.01 of the
corresponding one-stage designs. As expected, the most expensive study designs were the
one-stage study designs that genotyped all samples (excluding public controls – which
provide genotype data at no expense) on all SNPs. Significant cost savings were observed
when using the joint-analysis two-stage design described by Skol et al. (Skol et al., 2006).
For example, when utilizing the joint-analysis two-stage design following-up the top 1,500
SNPs (corresponding to the 1,536 SNP Illumina GoldenGate custom panel) in stage 2, a
36%, 44% and 60% cost savings was achieved relative to the corresponding one-stage
designs that included only study controls, only public controls and both public and study
controls, respectively. The total cost of our proposed replication-based two-stage design was
consistently less than the joint-analysis two-stage design that included both public and study
controls, though the latter design maintained greater power. The joint-analysis two-stage
design with only public controls was the least expensive design and had modestly greater
power than the replication-based two-stage design for most follow-up platforms. In addition
to having the lowest power among two-stage designs, the joint-analysis two-stage design
that included only study controls was substantially more expensive than any other two-stage
sampling design.
Discussion
We have performed a series of calculations to evaluate the statistical power of alternative
study designs that either includes public controls, study controls or both. We also describe a
novel replication-based two-stage design that uses freely available public control data in
stage 1, study controls in stage 2 and study cases genotyped in stages 1 and 2. For each
study design, we assessed the impact of both systematic ancestry differences between public
controls and study samples and batch genotype effects that could occur due to genotyping
public controls and study samples at different times on different genotyping platforms. Not
surprisingly, the single-stage study design with both public and study controls had the
greatest power under all circumstances considered. These results are entirely consistent with
previous reports that have shown the negative effects of disease misclassification on power
can be overcome by a using large number of unscreened controls (Edwards et al.,
2005;Moskvina et al., 2005;Wellcome Trust Case Control Consortium, 2007;Zheng and
Tian, 2005). While the single-stage study using only public controls generally had good
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power when the number of available public controls was large, we noted that inclusion of
the study controls protected power when there were strong differences in ancestry between
public controls and study cases or when there were relatively strong batch genotype effects
present. Under most circumstances, the proposed replication-based two-stage study had
greater power than the single-stage study with only study controls and, depending on the
circumstance, greater or lesser power than the single-stage study based only on public
controls.
Clearly the greatest cause for concern when using public control genotype data is that
observed allele frequency differences between public controls and study cases may be the
consequence of systematic bias due to population stratification or batch genotype effects
from differential allele calling between the two samples (Moskvina et al., 2006;Neale and
Purcell, 2008). Greater differences in background ancestry will likely occur between public
controls and study cases than between study cases and a carefully selected set of study
controls from the same community. The impact of population stratification can be largely
remedied by employing appropriate analytic methods (Price et al., 2006;Roeder and Luca,
2009;Yu et al., 2008), though these methods may not adequately alleviate biased results for
a relatively small number of genetic markers under strong selective pressure such as those
witnessed by the WTCCC study, that found highly significant differences in allele
frequencies for a small number of loci between individuals of Caucasian descent from
different communities in Great Britain (Wellcome Trust Case Control Consortium, 2007).
Results from several GWA studies that have included public control genotype data on
Caucasian samples have not revealed strong systematic differences in allele frequencies
between previously genotyped public controls and study samples (Hom et al., 2008;Luca et
al., 2008;Silverberg et al., 2009;Wrensch et al., 2009;Yu et al., 2008). However, results from
a recent study that used public controls have raised concerns about the impact of batch
genotype effects when cases and controls are genotyped on different platforms (Sebastiani et
al., 2010). In our examples, modest systematic differences in ancestry between public and
study samples had little impact on power (Table 3) or type I error (data not shown) when the
estimated proportion of ancestry for each subject was included as a covariate in the model.
These results are consistent with a recent report advocating the use of public controls
(Zhuang et al., 2010). Batch genotype effects, before and after accounting for systematic
batch effects across all SNPs, had either a negative or positive impact on power (Tables 4
and 5) and resulted in increased type I error rates for the SNP under consideration
(Supplementary Table 8). Still, the impact of batch genotype effects on the overall family-
wise error rate was small after applying the Genomic Control method (Reich and Goldstein,
2001) to account for the systematic inflation.
It is important to note that our examples did not include a small number of SNPs under
strong selective pressure or SNPs with extreme batch effects. The impact of including these
types of SNPs on overall statistical power would be minimal because, a priori, the
probability that a SNP under the alternative model is under such pressure is likely small.
However, a small number of SNPs under selective pressure or with extreme batch effects
would substantially inflate the family-wise error rate for the GWA study and this inflation
likely cannot be controlled by analytic methods. While a single-stage or a joint-analysis two-
stage study that includes both public and study controls provides the greatest power, there is
an increased possibility that any given significant result could be due to population
stratification or extreme batch effects. In contrast, the proposed replication-based two-stage
study maintains similar control of the overall type I error rate compared to a study based
only on study controls, making any single significant result more reliable. For example,
suppose that a single SNP, under the null hypothesis, with minor allele frequency of 0.30
has the major allele mistakenly scored the minor allele with probability = 0.15 in public
controls (increasing the frequency of the minor allele in this public control sample to 0.405).
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In a single-stage study design with 2,000 study cases, 2,000 study controls and 5,000 public
controls, this SNP would be significantly associated with the outcome with probability near
1 under the null of no true association between the SNP and outcome, hence the family-wise
error rate of the experiment would also be 1. In contrast, in the proposed replication-based
two-stage study the SNP would almost certainly be included in stage 2 but the overall
experimental type I error would be well controlled because the allele frequencies of the SNP
in study controls and remaining cases in stage 2 are unaffected by the batch effects in the
public controls in stage 1.
When considering which study design to use when including public controls, investigators
should consider the trade-offs between increased power and increased false positives when
choosing how to include public control genotype data in their study. Investigators should
also consider that reporting a large number of false positives could impact the power of
future replication studies due to the increased multiple test burden from following up a
larger number of variants. Study designs that include public controls in a single-stage or
joint-analysis two-stage design have more power than the proposed replication-based two-
stage design, however, these designs are also more susceptible to increased type I error rates.
The recent report by Sebastiani et al. (Sebastiani et al., 2010), that found evidence for
associations between 150 genetic variants and longevity based on a case-control sample
where cases and controls were disproportionately genotyped on different genotyping
platforms, highlights the potential severe impact of batch genotype effects. Our proposed
replication-based two-stage design is designed to protect the overall type I error of the
experiment while still increasing power and decreasing study costs compared to studies that
exclude public controls.
Finally, we have performed power calculations assuming fixed sample sizes rather than
fixed costs. As we have shown (Table 6), the inclusion of public control genotype data can
dramatically decrease the cost of genotyping in addition to increasing statistical power. With
this in mind, the increase in power between approaches that include public control data
compared to those that do not is even greater than what we have presented in situations
where the sample size of study subjects is limited by costs and not sample availability.
Optimizing power with respect to cost for each study design would require an iterative
application of the methods we have described. We have R software code that is available for
investigators who would like to calculate power and make the comparisons for their own
studies.
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Table 4
Statistical power calculations for one-stage study designs accounting for batch genotype effects between study
samples and public controls. Calculations assume 2,000 study cases, 2,000 study controls and 5,000 public
controls and M = 500,000 markers. Power calculated for a multiplicative genetic model with susceptibility
minor allele frequency = 0.3, K = 0.10 and GRR = 1.3 across different combinations of error rates for the two
genotyping platforms both before and after adjustment for mean systematic inflation in test statistics for SNPs
across the genome due to batch genotype effects.
Power
Error Rate Public
Controls Error Rate Study Samples
No Systematic Inflation Across
Genome Due to Batch Effects (μ
=1.0)
Systematic Inflation Across
Genome Due to Batch Effects*
Single Stage Design with Study Controls Only
 n.a. + 0.01 0.76 0.76
 n.a. 0.00 0.79 0.79
 n.a. − 0.01 0.77 0.77
Single Stage Design with Public Controls Only
 + 0.01 + 0.01 0.89 0.83
0.00 0.68 0.59
− 0.01 0.53 0.43
 0.00 + 0.01 0.98 0.96
0.00 0.90 0.85
− 0.01 0.82 0.74
 − 0.01 + 0.01 0.99 0.98
0.00 0.95 0.92
− 0.01 0.90 0.84
Single Stage Design with Study and Public Controls
 + 0.01 + 0.01 0.96 0.94
0.00 0.89 0.86
− 0.01 0.83 0.78
 0.00 + 0.01 0.99 0.99
0.00 0.97 0.96
− 0.01 0.94 0.92
 − 0.01 + 0.01 1.00 0.99
0.00 0.98 0.98
− 0.01 0.96 0.95
*
μ = 1.000, 1.100 and 1.056 for Study Controls Only, Public Controls Only, and Public and Study Controls, respectively.
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